Skip to main content

Table 3 Univariate analysis demonstrating factors associated with OS

From: Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study

Factor OS P-value HR (95% CI)
Treatment modality (CCRT vs chemotherapy) 0.011 0.626 (0.437–0.898)
Sex (male vs female) 0.677 0.918 (0.615–1.371)
Age (≤60 years vs > 60 years) 0.836 1.037 (0.734–1.465)
KPS score (≤80 vs > 80) 0.920 1.021 (0.679–1.536)
Primary tumor location
 cervical reference  
 upper thoracic 0.757 0.861 (0.333–2.225)
 middle thoracic 0.800 1.125 (0.450–2.812)
 lower thoracic 0.859 1.089 (0.427–2.774)
T- Stage (T1 + 2 vs T3 + 4) 0.096 0.667 (0.413–1.075)
N- Stage (N0 vs N+) 0.867 0.956 (0.566–1.615)
Dysphagia score
 0 (asymptomatic) reference  
 1 (eat solid diet with some dysphagia) 0.564 0.743 (0.272–2.034)
 2 (eat semisolid diet) 0.615 1.239 (0.537–2.858)
 3 (drink liquid diet) 0.880 1.063 (0.481–2.346)
 4 (complete dysphagia) 0.870 1.072 (0.466–2.467)
Number of metastases organs (solitary vs multiple metastasis) 0.013 0.621 (0.426–0.905)
Chemotherapy regimens (PTX + DDP vs 5-Fu + DDP) 0.109 0.747 (0.523–1.067)
Chemotherapy cycles (≤2 vs > 2) 0.910 1.021 (0.711–1.466)
  1. Abbreviations: CCRT concurrent chemoradiotherapy, KPS Karnofsky Performance Status, CDDP cisplatin, 5-FU 5-fluorouracil, PTX paclitaxel, HR hazard ratio, CI confidence interval, OS overall survival